转移性三阴性乳腺癌患者的治疗模式和临床结果:使用日本索赔数据库进行大规模数据分析
Takayuki Kimura1, Tomoko Takami2, Yi Piao2
1Medical Affairs, Gilead Sciences K.K., Tokyo, Japan. Takayuki.Kimura@gilead.com.
Breast cancer research and treatment
|May 5, 2024
概括
日本的现实数据显示了转移性三阴性乳腺癌 (mTNBC) 治疗模式. 后期治疗方法的回报正在下降,并突出了对有效的mTNBC药物治疗的未满足需求.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
- 卫生经济学 卫生经济学
背景情况:
- 转移性三阴性乳腺癌 (mTNBC) 存在重大治疗挑战.
- 了解现实世界治疗模式对于优化日本患者护理至关重要.
研究的目的:
- 在日本现实环境中评估mTNBC的治疗模式和临床结果.
- 分析治疗序列,到下一次治疗或死亡的时间 (TTNTD),不良事件和成本.
主要方法:
- 日本医疗索赔数据库的回顾性分析 (2017年1月至2022年3月).
- 包括2236名mTNBC患者在一线,二线和三线治疗环境中.
- 治疗方案根据日本乳腺癌协会指导方针进行分类.
主要成果:
- 皮他和S-1是常见的第一线治疗;埃里布林和贝瓦西祖马布/帕克利塔塞尔在第二和第三线设置中普遍存在.
- 随着随后的治疗线路 (中位数为8.0个月,6.5个月,5.2个月) 的TTNTD下降.
- 常见的不良事件包括恶心/吐和中性质衰竭/白血病;每日医疗费用随着治疗线路的增加而增加.
结论:
- 日本目前的mTNBC治疗模式显示,后一线疗法效率较短的趋势.
- 后期治疗线路的成本效益比下降,表明对新型mTNBC药物的大量未满足需求.
更多相关视频
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.0K
08:32Using Computer-based Image Analysis to Improve Quantification of Lung Metastasis in the 4T1 Breast Cancer Model
Published on: October 2, 2020
6.3K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
